BANK VONTOBEL/CALL/ELI LILLY & CO/620/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 13:54:59 2024-06-25 EDT | ||
| 27.45 EUR | +1.97% |
|
| Current month | +43.04% | ||
| 1 month | +45.62% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 27.45 | +1.97% |
| 24-06-24 | 26.92 | +3.98% |
| 24-06-21 | 25.89 | +3.64% |
| 24-06-20 | 24.98 | -5.74% |
| 24-06-19 | 26.5 | +2.67% |
Delayed Quote Deutsche Boerse AG
Last update June 25, 2024 at 01:54 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VM3L3W |
| ISIN | DE000VM3L3W7 |
| Date issued | 2023-10-06 |
| Strike | 620 $ |
| Maturity | 2024-09-20 (87 Days) |
| Parity | 10 : 1 |
| Emission price | 4.13 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 27.45 € |
|---|---|
| Lowest since issue | 4.61 € |
| Spread | 0.02 € |
| Spread % | 0.07% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
904.6
USD
Average target price
860.5
USD
Spread / Average Target
-4.87%
- Stock Market
- Warrants
- Warrant
